ImmunityBio (IBRX) Capital Expenditures Growth (1y) (2015 - 2025)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 227.76% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 0.57% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 143.40% |
| 10 | ImmunityBio | 7.72 Bn | 7.34 Bn | 43.97 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 118.90% |
| Sep 30, 2025 | -41.30% |
| Jun 30, 2025 | 80.11% |
| Dec 31, 2024 | -160.05% |
| Sep 30, 2024 | -73.75% |
| Jun 30, 2024 | 110.28% |
| Mar 31, 2024 | -93.37% |
| Dec 31, 2023 | 3,451.34% |
| Sep 30, 2023 | 1,179.90% |
| Jun 30, 2023 | -156.81% |
| Mar 31, 2023 | 1,693.87% |
| Dec 31, 2022 | 101.95% |
| Sep 30, 2022 | -106.65% |
| Jun 30, 2022 | 203.75% |
| Mar 31, 2022 | -75.13% |
| Dec 31, 2021 | -1,546.07% |
| Jun 30, 2021 | 103.90% |
| Mar 31, 2021 | 1,062.67% |
| Dec 31, 2020 | -189.04% |
| Jun 30, 2020 | 376.76% |
| Mar 31, 2020 | -81.93% |
| Dec 31, 2019 | 112.28% |
| Sep 30, 2019 | -40.10% |
| Jun 30, 2019 | -129.01% |
| Mar 31, 2019 | -58.57% |
| Dec 31, 2018 | 53.95% |
| Sep 30, 2018 | -65.82% |
| Jun 30, 2018 | -69.45% |
| Mar 31, 2018 | 8.72% |
| Dec 31, 2017 | -1,122.24% |
| Sep 30, 2017 | 248.07% |
| Jun 30, 2017 | 672.35% |
| Mar 31, 2017 | 322.59% |
| Dec 31, 2016 | 42.20% |
| Sep 30, 2016 | 171.52% |
| Jun 30, 2016 | 826.32% |
| Mar 31, 2016 | 2,707.89% |
| Dec 31, 2015 | 2,481.08% |
| Sep 30, 2015 | 526.52% |